Mollie Dewsbury

Ms. Mollie Dewsbury


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DMDavid Mantle
David Mantle
MDMollie Dewsbury
Mollie Dewsbury
Iain HargreavesIain Hargreaves
Iain Hargreaves
Coenzyme Q10 (CoQ10) plays a key role in many aspects of cellular metabolism. For CoQ10 to function normally, continual interconversion between its oxidised (ubiquinone) and reduced (ubiquinol) forms is required. Given the central importance of this ubiquinone–ubiquinol redox cycle, this article reviews what is currently known about this process and the implications for clinical practice. In mitochondria, ubiquinone is reduced to ubiquinol by Complex I or II, Complex III (the Q cycle) re-oxidises ubiquinol to ubiquinone, and extra-mitochondrial oxidoreductase enzymes participate in the ubiquinone–ubiquinol redox cycle. In clinical terms, the outcome of deficiencies in various components associated with the ubiquinone–ubiquinol redox cycle is reviewed, with a particular focus on the potential clinical benefits of CoQ10 and selenium co-supplementation.

11 April 2024 in Oxygen
Verified
Journal Article
Open access
PDF file
DMDavid Mantle
David Mantle
HRHannah Rowbottom
Hannah Rowbottom
JJJacob Jones
Jacob Jones
IPIndiia Margarita Potts
Indiia Margarita Potts
NTNadia Turton
Nadia Turton
Iain HargreavesIain Hargreaves
Iain Hargreaves
The generation of energy within cells is a fundamental process enabling cell survival, and as such it represents a potential target in cancer therapy. In this article, we therefore review the relative contributions of glycolysis and oxidative phosphorylation/mitochondrial function to cancer cell energy generation, and we highlight their respective potential value as chemotherapeutic targets. This article is particularly focussed on the potential role of coenzyme Q10 in the prevention and treatment of cancer.

28 October 2025 in Genes
Verified
Journal Article
Open access
PDF file
MDMollie Dewsbury
Mollie Dewsbury
TPTyler Purcell
Tyler Purcell
DHDerralynn Hughes
Derralynn Hughes
ADAimee Donald
Aimee Donald
Iain HargreavesIain Hargreaves
Iain Hargreaves
KSKarolina M Stepien
Karolina M Stepien
Gaucher disease (GD) is an autosomal recessive metabolic disorder caused by pathogenic variants in the GBA1 gene, which encodes the lysosomal hydrolase β-glucocerebrosidase (GCase). The pathogenic defects result in a misfolded protein, which can trigger endoplasmic reticulum stress and an unfolded protein response within the affected cells. The reduced enzyme activity leads to accumulation of its substrates, glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), within lysosomes or macrophages and with prominent disease manifestations in reticuloendothelial tissues such as liver, spleen and bone marrow. GCase defects alter both the mitochondria and the lysosome. In the lysosome, reduced GCase activity leads to glycosphingolipid build-up, disrupting lysosomal function and autophagy, thereby activating α-synuclein accumulation. GCase can also be imported into the mitochondria, where it fosters the integrity and function of mitochondrial respiratory chain (MRC) complex I. Thus, the reduced GCase activity impairs the normal mitochondrial function and increases oxidative stress in this organelle, which may contribute to cell death. However, further studies are required to confirm this mechanism of MRC dysfunction. In this review we have systematically evaluated the evidence for oxidative stress in individuals affected by GD, as well as the currently available therapies and adjunctive therapies. Therapies targeting oxidative stress may prove useful as adjuvant treatments for GD.

Verified
Journal Article
Open access
PDF file
DMDavid Mantle
David Mantle
MDMollie Dewsbury
Mollie Dewsbury
AMAlexander David Mendelow
Alexander David Mendelow
Iain HargreavesIain Hargreaves
Iain Hargreaves
The incidence of morbidity and mortality in patients who have suffered traumatic brain injury (TBI) is such that novel therapeutic strategies are currently required. There is good evidence that ischaemia is the primary, and sometimes the secondary, cause of brain damage in TBI. This ischaemia may lead to mitochondrial dysfunction, with associated oxidative stress and inflammation, in the pathogenesis of brain injury following head trauma. This, in turn, provides a rationale for the use of supplemental coenzyme Q10 (CoQ10) in the management of TBI, given its key roles in normal mitochondrial function and as an antioxidant and anti-inflammatory agent. In this article, we, therefore, review the use of supplemental CoQ10 in animal models of TBI and its potential application in the management of TBI patients. The problem of blood–brain barrier access is discussed, and how this might be circumvented via the use of an intranasal route to provide direct access of CoQ10 to the brain. In addition, there is evidence that TBI patients have an increased risk of developing cardiac dysfunction and that this may be mediated by aberrant immune action. Given the role of CoQ10 in promoting normal cardiac function and normal immune function, the administration of CoQ10 to prevent cardiovascular complications may improve outcomes in TBI patients.

28 December 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
DMDavid Mantle
David Mantle
NCNeve Cufflin
Neve Cufflin
MDMollie Dewsbury
Mollie Dewsbury
Iain HargreavesIain Hargreaves
Iain Hargreaves
The disparity in outcomes between preclinical and clinical studies supplementing coenzyme Q10 (CoQ10) in neurological disorders may be a reflection of the differences in the ability of supplemental CoQ10 to access the blood–brain barrier (BBB) in rodents and in humans, which is, in turn, a consequence of contrasting structures of the BBB. The applicability of in vivo animal models to study access of CoQ10 across the BBB and subsequent neuronal metabolism has, therefore, been questioned, and there is an argument, perhaps surprisingly, that in vitro model systems (particularly 3D cellular systems) may be more appropriate. In this article, we have, therefore, reviewed the role of model systems to study the access of CoQ10 across the BBB, as well as the role of such systems in studying the role of CoQ10 in aspects of neuronal metabolism, such as mitochondrial and lysosomal function. In addition, the use of such model systems to study the interactions of CoQ10 with vitamin E and selenium has been reviewed. Finally, the practical application of a neuronal model system to investigate the effect of CoQ10 supplementation on CoQ10 status and mitochondrial metabolism in a CoQ10 deficiency state has been described.